Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allocetra-OTS in End Stage Knee Osteoarthritis
NCT06208241Phase 1Active, not recruiting
- Start
- Jul 2023
- Primary completion
- Sep 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Allocetra in knee osteoarthritis (OA). Primary endpoint: Treatment-emergent adverse events and Serious adverse events at 6 months. Started Jul 2023; status: active, not recruiting.
02
Drugs
Allocetra
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06208241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06208241.